Skip to Content


In the US, Tocilizumab (tocilizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Cytokine Release Syndrome, Giant Cell Arteritis, Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Still's Disease and Systemic Sclerosis.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories


Monoclonal antibody

Chemical Name

immunoglobulin G1, anti-(human interleukin 6 receptor) (human-mouse monoclonal MRA heavy chain), disulfide wit human-mouse monoclonal MRA kappa-chain, dimer (WHO)

Foreign Names

  • Tocilizumabum (Latin)
  • Tocilizumab (German)
  • Tocilizumab (French)
  • Tocilizumab (Spanish)

Generic Names

Brand Names

  • Actembra
    Roche, Egypt
  • Actemra
    Chugai, Georgia; Chugai Pharma, Oman; Chugai Pharmaceutical, Japan; F. Hoffmann-La Roche, Macedonia; Galenika AD, Serbia; Genentech, United States; Hoffmann-La Roche, Canada; Productos Roche, Chile; Roche, Armenia; Roche, Netherlands Antilles; Roche, Argentina; Roche, Aruba; Roche, Azerbaijan; Roche, Bosnia & Herzegowina; Roche, Belarus; Roche, Ecuador; Roche, Hong Kong; Roche, India; Roche, Kyrgyzstan; Roche, Moldova; Roche, Myanmar; Roche, Malaysia; Roche, New Zealand; Roche, Oman; Roche, Peru; Roche, Philippines; Roche, Paraguay; Roche, Russian Federation; Roche, Thailand; Roche, Turkmenistan; Roche, Tunisia; Roche, Uruguay; Roche, Vietnam; Roche, South Africa; Roche D.O.O., Serbia; Roche Products, Australia; Vetter, Georgia; Vetter, Russian Federation; Roche Pharma Schweiz, Switzerland
    Roche Pharmaceutical, China
  • Actemra 162mg
    Roche, Israel
  • Actemra 200mg/10ml
    Roche, Turkey
  • Actemra 20mg/ml
    Roche, Israel
  • Actemra 400mg/20ml
    Roche, Turkey
  • Actemra 80mg/4ml
    Roche, Turkey
  • Acterma
    Chugai Pharma, Kenya; Roche, Brazil
  • Acterma SC
    Roche, Brazil
  • Aktempa
    Roche, Ukraine
  • Roaccutane
    Roche, Cyprus
  • RoActemra
    Hoffmann-La Roche Ltd, Latvia; Roche, Belgium; Roche, Czech Republic; Roche, Denmark; Roche, Estonia; Roche, Spain; Roche, Finland; Roche, France; Roche, Greece; Roche, Croatia (Hrvatska); Roche, Ireland; Roche, Lithuania; Roche, Mexico; Roche, Norway; Roche, Poland; Roche, Sweden; Roche - Germania, Romania; Roche Products, United Kingdom; Roche Registration, Netherlands; Roche Registration Limited, Iceland; Roche Registration, Slovenia
  • RoActemra 162 mg
    Roche, Hungary
  • RoActemra 162mg
    Chugai Pharma, Germany; Roche, Germany; Roche, Luxembourg; Roche Registration, Austria
  • RoActemra 20 mg/ml
    Roche, Hungary
  • RoActemra 20mg/ml
    Chugai Pharma, Germany; Roche, Germany; Roche, Luxembourg; Roche Registration, Austria


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.